Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Long-Term Deferred Tax (2016)

IGC Pharma (IGC) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $19000.0 as the latest value for Q4 2016.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $19000.0 in Q4 2016 year-over-year; TTM through Dec 2016 was $19000.0, a N/A change, with the full-year FY2016 number at $356684.0, up 11.97% from a year prior.
  • Long-Term Deferred Tax was $19000.0 for Q4 2016 at IGC Pharma, down from $356684.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $356684.0 in Q1 2016 to a low of -$14076.0 in Q1 2012.
  • A 5-year average of $259590.1 and a median of $317390.5 in 2013 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: soared 2525.8% in 2013, then fell 5.79% in 2014.
  • IGC Pharma's Long-Term Deferred Tax stood at -$14076.0 in 2012, then surged by 2221.59% to $298635.0 in 2013, then increased by 7.72% to $321676.0 in 2014, then dropped by 3.16% to $311509.0 in 2015, then tumbled by 93.9% to $19000.0 in 2016.
  • Per Business Quant, the three most recent readings for IGC's Long-Term Deferred Tax are $19000.0 (Q4 2016), $356684.0 (Q1 2016), and $311509.0 (Q3 2015).